Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS)

Anna Rita Ghezzi; Maurizio Aceto; Claudio Cassino; Elisabetta Gabano; Domenico Osella

doi:10.1016/j.jinorgbio.2003.08.014

Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS)

Anna Rita Ghezzi
, Maurizio Aceto
, Claudio Cassino
, Elisabetta Gabano
, Domenico Osella

Department of Sustainable Development and Ecological Transition

Research output: Contribution to journal › Article › peer-review

Abstract

A systematic study on intracellular Pt uptake and Pt accumulation ratio in breast cancer MCF-7 cell line has been performed on a number of Pt(II)-complexes, namely cisplatin, carboplatin and oxaliplatin, clinically employed as antitumor drugs, trans- and cis-[Pt(Cl)₂(pyridine) ₂] and cis-[Pt(Cl)₂(pyridine)(5-SO₃H- isoquinoline)] complexes, previously investigated also as potential telomerase inhibitors. In particular, long incubation times have been chosen in order to understand the fate of the complexes in the cells. For this purpose, sub-acute drug concentrations must be employed and, therefore, a very sensitive method of analysis like as inductively coupled plasma mass spectrometry (ICP-MS) superior to the widely employed atomic absorption spectroscopy (AAS) has been adopted. Any relationships among uptake/accumulation and several parameters such as drug structure, lipophilicity, drug concentration and incubation time have been sought and analyzed: the bulk of data point for a passive diffusion mechanism through the cell membrane.

Original language	English
Pages (from-to)	73-78
Number of pages	6
Journal	Journal of Inorganic Biochemistry
Volume	98
Issue number	1
DOIs	https://doi.org/10.1016/j.jinorgbio.2003.08.014
Publication status	Published - Jan 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antitumor chemotherapy
Cisplatin-like complexes
ICP-MS
Platinum uptake

Access to Document

10.1016/j.jinorgbio.2003.08.014

Cite this

@article{f66f3b9175e34eaa97656fc8f0ccf82d,

title = "Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS)",

abstract = "A systematic study on intracellular Pt uptake and Pt accumulation ratio in breast cancer MCF-7 cell line has been performed on a number of Pt(II)-complexes, namely cisplatin, carboplatin and oxaliplatin, clinically employed as antitumor drugs, trans- and cis-[Pt(Cl)2(pyridine) 2] and cis-[Pt(Cl)2(pyridine)(5-SO3H- isoquinoline)] complexes, previously investigated also as potential telomerase inhibitors. In particular, long incubation times have been chosen in order to understand the fate of the complexes in the cells. For this purpose, sub-acute drug concentrations must be employed and, therefore, a very sensitive method of analysis like as inductively coupled plasma mass spectrometry (ICP-MS) superior to the widely employed atomic absorption spectroscopy (AAS) has been adopted. Any relationships among uptake/accumulation and several parameters such as drug structure, lipophilicity, drug concentration and incubation time have been sought and analyzed: the bulk of data point for a passive diffusion mechanism through the cell membrane.",

keywords = "Antitumor chemotherapy, Cisplatin-like complexes, ICP-MS, Platinum uptake",

author = "Ghezzi, \{Anna Rita\} and Maurizio Aceto and Claudio Cassino and Elisabetta Gabano and Domenico Osella",

note = "Funding Information: This work was financially supported by MIUR (Roma) within PRIN2001 project. We are indebted to Johnson and Matthey (Reading, UK) for a generous loan of K 2 PtCl 4 . AR.G. thanks CIRCMSB (Bari) for research fellowship. This research was carried out in the frame of the European Cooperation Cost D20 action (Metal compounds in the treatment of cancer and viral diseases) and Cost B16 action (Multidrug resistance reversal).",

year = "2004",

month = jan,

doi = "10.1016/j.jinorgbio.2003.08.014",

language = "English",

volume = "98",

pages = "73--78",

journal = "Journal of Inorganic Biochemistry",

issn = "0162-0134",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS)

AU - Ghezzi, Anna Rita

AU - Aceto, Maurizio

AU - Cassino, Claudio

AU - Gabano, Elisabetta

AU - Osella, Domenico

N1 - Funding Information: This work was financially supported by MIUR (Roma) within PRIN2001 project. We are indebted to Johnson and Matthey (Reading, UK) for a generous loan of K 2 PtCl 4 . AR.G. thanks CIRCMSB (Bari) for research fellowship. This research was carried out in the frame of the European Cooperation Cost D20 action (Metal compounds in the treatment of cancer and viral diseases) and Cost B16 action (Multidrug resistance reversal).

PY - 2004/1

Y1 - 2004/1

N2 - A systematic study on intracellular Pt uptake and Pt accumulation ratio in breast cancer MCF-7 cell line has been performed on a number of Pt(II)-complexes, namely cisplatin, carboplatin and oxaliplatin, clinically employed as antitumor drugs, trans- and cis-[Pt(Cl)2(pyridine) 2] and cis-[Pt(Cl)2(pyridine)(5-SO3H- isoquinoline)] complexes, previously investigated also as potential telomerase inhibitors. In particular, long incubation times have been chosen in order to understand the fate of the complexes in the cells. For this purpose, sub-acute drug concentrations must be employed and, therefore, a very sensitive method of analysis like as inductively coupled plasma mass spectrometry (ICP-MS) superior to the widely employed atomic absorption spectroscopy (AAS) has been adopted. Any relationships among uptake/accumulation and several parameters such as drug structure, lipophilicity, drug concentration and incubation time have been sought and analyzed: the bulk of data point for a passive diffusion mechanism through the cell membrane.

AB - A systematic study on intracellular Pt uptake and Pt accumulation ratio in breast cancer MCF-7 cell line has been performed on a number of Pt(II)-complexes, namely cisplatin, carboplatin and oxaliplatin, clinically employed as antitumor drugs, trans- and cis-[Pt(Cl)2(pyridine) 2] and cis-[Pt(Cl)2(pyridine)(5-SO3H- isoquinoline)] complexes, previously investigated also as potential telomerase inhibitors. In particular, long incubation times have been chosen in order to understand the fate of the complexes in the cells. For this purpose, sub-acute drug concentrations must be employed and, therefore, a very sensitive method of analysis like as inductively coupled plasma mass spectrometry (ICP-MS) superior to the widely employed atomic absorption spectroscopy (AAS) has been adopted. Any relationships among uptake/accumulation and several parameters such as drug structure, lipophilicity, drug concentration and incubation time have been sought and analyzed: the bulk of data point for a passive diffusion mechanism through the cell membrane.

KW - Antitumor chemotherapy

KW - Cisplatin-like complexes

KW - ICP-MS

KW - Platinum uptake

UR - https://www.scopus.com/pages/publications/0344255614

U2 - 10.1016/j.jinorgbio.2003.08.014

DO - 10.1016/j.jinorgbio.2003.08.014

M3 - Article

SN - 0162-0134

VL - 98

SP - 73

EP - 78

JO - Journal of Inorganic Biochemistry

JF - Journal of Inorganic Biochemistry

IS - 1

ER -

Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS)

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this